Shares of ImmunityBio IBRX were up 11% on Monday after the company announced that Macau’s regulatory body has approved its lead drug, Anktiva, for treating certain patients with a type of bladder ...

ImmunityBio’s IBRX growth narrative is increasingly tied to the expansion potential of its sole marketed drug, Anktiva, ...

ImmunityBio (IBRX) stock falls as the FDA issues a warning letter regarding a TV commercial and a podcast related to the ...

FDA has issued a warning letter to ImmunityBio over allegedly misleading promotional materials for its bladder cancer therapy Anktiva. The letter raises concerns about how the company is communicating ...

ImmunityBio (IBRX) stock plummeted 21% after the FDA issued a warning letter citing false advertising claims about its ...

ImmunityBio Inc (NASDAQ: IBRX) is under immense pressure on March 24 after the US Food and Drug Administration (FDA) issued a ...

In today's Pharmaceutical Executive Daily, the FDA issues a warning letter to ImmunityBio over misleading promotional claims ...

The FDA this month issued a warning letter to ImmunityBio regarding promotional statements about cancer drug Anktiva that the ...

Norwegian bladder cancer specialist Photocure and its Chinese partner Asieris Pharmaceuticals have announced that Cevira (hexaminolevulinate hydrochloride ointment photodynamic therapy system) was ...

Both ImmunityBio IBRX and Moderna MRNA are biotech firms that depend largely on the successful commercialization of a single ...

ImmunityBio faces significant regulatory pressure and a sharp decline in its share price following a formal reprimand from the U.S. Food and Drug Administration (FDA). The agency issued a warning ...

From air pollution to microplastics to natural radiation, these are the environmental factors that contribute to cancer risk ...